Although a significant increment of OX-A or 2-AG levels has been documented in the plasma of AD patients (Koppel et al., 2009; Altamura et al., 2015), the possible 2-AG-derived production of 2-AGP and the phosphorylation of Tau as a downstream effect of 2-AGP signaling at LPA1R, have not been yet addressed. The gene discussed is MAPT; the disease is Alzheimer disease.